US Patent

US8293752 — Compounds useful as Raf kinase inhibitors

Composition of Matter · Assigned to Millennium Pharmaceuticals Inc · Expires 2031-08-04 · 5y remaining

Vulnerability score 23/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that inhibit the Raf protein kinase and compositions and methods for treating diseases mediated by Raf.

USPTO Abstract

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Drugs covered by this patent

Patent Metadata

Patent number
US8293752
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-08-04
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Millennium Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.